plasma glucose (>100 mg/dL) and triglycerides (TGs; >200 mg/dL).
None of the subjects in both groups were on statins, angiotensin receptor blockers, fibrates, aspirin or peroxisome proliferator-activated receptor (PPAR) gamma agonists. MetS patients were on diuretics, beta blockers or angiotensin-converting enzyme (ACE) inhibitors (n = 2) for their hypertension. All subjects had a high-sensitive C-reactive protein (hsCRP) <10 mg/L and normal white cell and neutrophil counts and had no acute or chronic inflammatory diseases or recent infection. All other exclusion criteria including smoking, albuminuria >30 mg/G creatinine and clinical CVDs are detailed in previous publications. 3, 4 Informed consent was obtained from participants in the study, which was approved by the institutional review board at the University of California Davis. All human investigation was conducted according to the principles expressed in the Declaration of Helsinki. After history and physical examination, fasting blood was obtained for basic chemistries, hsCRP, homeostasis model assessment (HOMA) calculation and monocyte isolation as described previously. 3, 4 
Monocyte isolation and cell signalling studies
Monocytes were isolated from fasting heparinized blood by Ficoll-Hypaque density gradient centrifugation followed by negative magnetic separation as described previously. 3 Using CD14 staining, >92% of the cells were identified to be monocytes. Monocyte lysates and nuclear extracts were prepared as described previously. 3 Phosphorylated and total p38 MAPK, extracellular signalregulated kinase-1/2 (ERK1/2), and c-Jun N-terminal kinase (JNK), activity in the cell lysates and nuclear factor (NF)-κB p65 activity in the nuclear extracts were assessed using reagents from Bio-Rad using the Bioplex multiplex phosphoprotein detection assays following the manufacturer's instructions. 5 We have previously validated these multiplex assays with western blots. 5 The principle of these bead-based assays is similar to a capture sandwich immunoassay. The assays use microscopic beads each with a different colour code (spectral address) to permit discrimination of individual phospho and total proteins. Briefly, 50 µL of internally dyed microbeads (1×) each coupled to antibodies directed against a different target phosphoprotein or total protein was added per well of 96-well plate. Thereafter, 25 µL of the cell lysate was added to each well and incubated overnight at 25°C on a plate shaker. Following repeated washing, 25 µL of biotinlabelled detection antibodies for each target was added per well of the plate for 30 min. Streptavidin-phycoerythrin conjugated fluorescent reporter was added to each well of the plate in dark following further washes. Data were acquired on multiplex plate reader. The dyed beads were identified by their internal fluorescent signature, and the level of target bound to beads was indicated by the intensity of reporter signal for the phospho and total MAPKs. The intra-assay coefficients of variations of the assays were <14%.
Statistical analysis
Results are expressed as mean and standard deviation (SD) or as median and interquartile range for skewed variables. Log transformations were applied to variables with skewed distributions prior to parametric analyses. Comparisons between the control and MetS groups were made with twosample t-tests and analysis of covariance to control for age, body mass index (BMI) and waist circumference (WC). The association of phospho-p38 MAPK with the number of features of MetS and p trend was derived using the Jonckheere-Terpstra test. Combining the control and MetS groups, Spearman's rank correlation coefficients were computed to assess the association of metabolic variables and the phospho-p38 MAPK variables. Data were analysed using SAS version 9.4 (SAS Institute, Cary, NC).
Results
As shown in Table 1 , patients with MetS were balanced for age and gender but had significant differences in all features of MetS and increased hsCRP and homeostasis model assessment-estimated insulin resistance (HOMA-IR).
With respect to monocyte MAPKs, there was a significant increase in phospho-p38/p38 MAPK ratio in MetS which persisted following adjustment for BMI and WC with no significant differences for pERK/ERK1/2 and pJNK/ JNK (Table 1) . Also phospho-p38 MAPK increased with increasing features of MetS (p < 0.001 for trend) and correlated significantly with all features: WC (r = 0.35, p = 0.002), glucose (r = 0.46, p < 0.001), TGs, (r = 0.53, p < 0.001), blood pressure systolic (r = 0.38, p = 0.001) and high-density lipoprotein (HDL) cholesterol (r = −0.27, p = 0.02).
Since we have reported increased inflammation and oxidative stress previously, 3, 4 correlations were undertaken between these variables and p38 MAPK activity. Phospho-p38 MAPK correlated significantly with HOMA-IR (r = 0.40, p = 0.005), hsCRP (r = 0.33, p = 0.005), interleukin-6 (IL-6; r = 0.38, p = 0.0009), interleukin-8 (IL-8; r = 0.32, p = 0.006), soluble tumour necrosis factor receptor-1 (sTNFR-1; r = 0.49, p = 0.001), toll-like receptor 2 (TLR2; r = 0.30, p = 0.01), toll-like receptor 4 (TLR4; r = 0.39, p = 0.001), phospho-NF-κB p65 (r = 0.56, p < 0.001), basal superoxide secretion (r = 0.33, p = 0.004) and oxidized low-density lipoprotein (LDL) levels (r = 0.60, p < 0.001). There was a trend to significance with interleukin-1 (IL-1; r = 0.23, p = 0.05).
Since two of our patients in this report were on ACE inhibitors which are known to inhibit MAPKs, 6, 7 we repeated all analyses following exclusion of these two patients. All the above repeated findings remained the same.
Conclusion
There are scanty data with respect to cell signalling in MetS. Previously, it has been shown that there is altered mRNA expression or protein abundance of receptors on monocytes of patients with MetS. 2 To date, an increase in CD40, CD32, CD64, CCR5, TLR2 and TLR4 with a decrease in PPAR alpha and delta and the Vitamin D receptor has been reported. 2 However, signal transduction was only pursued with respect to monocyte TLR2 and TLR4 showing increased NF-κB activity and downstream biomediators. 3 Since the TLRs also signal through MAPKs, 8 we investigated MAPK activity in this report. The three well-defined sub-groups of MAPKs in mammalian cells are the ERK1/2, the JNK and the p38 MAPKs. 9 We show a significant increase in p38 MAPK activity even following adjustment for both BMI and WC. However, we failed to show an increase in ERK1/2 and JNK. The major focus of studies on the MAPK family is based on their role in impairing insulin signalling. 10 In a similar model of polycystic ovary syndrome in women, they showed an increase in basal ERK1/2 activity in skeletal muscle but no change in p38 activity. 11 However, in diabetic patients, in both skeletal muscle and adipose tissue, increase in p38 MAPK activity was reported. 12, 13 Koistinen et al. 12 showed an increase in basal p38 activity in skeletal muscle. Carlson et al. 13 showed a significant increase in basal p38, JNK and ERK1/2 with the greatest increase in p38 (5-fold) which contributed to loss of glucose transporter type 4 (GLUT4) expression. We also show in MetS a significant correlation with insulin resistance as determined by HOMA-IR.
P38 MAPK activity has been suggested to contribute to inflammation. [14] [15] [16] We show that p38 MAPK activity correlated with biomediators of increased inflammation: TLR2 and TLR4, CRP, NF-κB activity, IL-6, IL-8 and sTNFR-1 in patients with MetS. Hence, in patients with MetS, this could be an additional molecular target to attenuate both insulin resistance and inflammation, the major pathophysiology underlying this disorder. 1, 2 To date, it is unclear what triggers the increase in p38 MAPK activity. It has been suggested that oxidative stress is one such stressor. 9 In our study, we show a significant correlation with both oxidized LDL and basal nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) oxidase activity (superoxide anion). While correlations cannot infer causality, this data support the link proposed in the published literature.
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